PDF) WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: Study protocol for a prospective, multi-center, controlled, non-blinded, randomized ...
Adaptive design (medicine) - Wikipedia
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial - The Lancet Oncology
ADAPT HER2+/HR+ trial design. HER2+/HR+ patients receive either T-DM1... | Download Scientific Diagram
Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status? - Nadia Harbeck, 2018
Case 3: POETIC and ADAPT Trials in HR+ High-Risk Breast Cancer
OncoAlert on X: "The #OncoAlertTopTweet 🚨Day5⃣of #ESMO21 Tweet @Dr_Ivanoncologo Dr. Harbeck: Predictive impact of biomarkers🎯on pCR and survival after de-escalated neoadjuvant T-DM1 w/ or w/o endocrine therapy (ET) vs Trastuzumab🧪+ ET in
Immunotherapy for early triple negative breast cancer: research agenda for the next decade | npj Breast Cancer
WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator ...
Cancers | Free Full-Text | ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 ...
De-escalated neoadjuvant paclitaxel, dual HER2 blockade effective in breast cancer subtype
Frontiers | Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges
Metastatic triple negative breast cancer adapts its metabolism to destination tissues while retaining key metabolic signatures | PNAS
Using Neoadjuvant Endocrine Therapy to Understand Resistance in Breast Cancer
CONSORT diagram. Disposition of patients in the ADAPT (Adjuvant Dynamic... | Download Scientific Diagram
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer - ScienceDirect
Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow - ScienceDirect
S5-03 Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant
The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer in: Journal of the National Comprehensive Cancer Network Volume 20 Issue 6 (2022)
Cancers | Free Full-Text | Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study - The Lancet Diabetes & Endocrinology
ADAPT Triple Negative trial design. Triple negative (HER2-/HR-)... | Download Scientific Diagram
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic | npj Breast Cancer
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 ...
Susan G. Komen on X: "WSG ADAPT HR-/HER2+ phase II trial showed improved pathological complete response (pCR) and survival in patients treated by #de-escalated chemotherapy, pertuzumab, and trastuzumab. Early pCR strongly associated
